Thiazolidinediones: New evidence of bone loss

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 4, 2007, Pages 1232-1234

  Schwartz, Ann V ^a   Sellmeyer, Deborah E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; GLIBENCLAMIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FRACTURE; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MENOPAUSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT;

EID: 34147156666     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0328     Document Type: Editorial

References (19)

1. Lecka-Czernik B, Suva LJ 2006 Resolving the two "bony" faces of PPAR-γ. PPAR Res 2006:1-9
2. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR 2006 Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
3. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR 2007 The peroxisome-proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310
4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
5. Vestergaard P 2007 Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 18:427-444
6. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406
7. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216
8. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235
9. Sottile V, Seuwen K, Kneissel M 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337
10. Hangartner TN, Johnston CC 1990 Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner 9:71-81
11. Kuiper JW, van Kuijk C, Grashuis JL, Ederveen AG, Schutte HE 1996 Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro. Osteoporos Int 6:25-30
12. Jennermann C, Triantafillou J, Cowan D, Pennink B, Connolly K, Morris D 1995 Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res 10(Suppl 1):S241 (Abstract)
13. Syversen U, Bakke I, Aune G, Thommesen L 2003 PPAR-α agonists increase bone mineral density in female rats. J Bone Miner Res 18(Suppl 2):S42 (Abstract)
14. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M 2001 Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69:46-50
15. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166-171
16. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
17. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B 2006 Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone 38:74-84
18. Krishnan V, Bryant HU, Macdougald OA 2006 Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202-1209
19. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ 2007 Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903-911